Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2018

01-12-2018 | Correspondence

Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994–2013)

Authors: R. Fuentes-Raspall, M. Solans, C. Auñon-Sanz, M. Saez, R. Marcos-Gragera

Published in: Clinical and Translational Oncology | Issue 12/2018

Login to get access

Excerpt

In a recent publication [1], we presented incidence and survival of malignant and non-malignant central nervous system (CNS) tumors in the Girona Province (1994–2013). The study included primary central nervous system lymphoma (PCNSL) cases, a rare, aggressive form of an extra nodal lymphoma that exclusively affects the CNS. We would like to draw attention toward these results, given that epidemiological data about PCNSL remain notably limited, in particular for Southern Europe regions, where only one French study has previously reported incidence rates [2]. …
Literature
1.
Fuentes-Raspall R, Solans M, Roca-Barceló A, Vilardell L, Puigdemont M, Del Barco S, Comas R, Garcia-Velasco A, Astudillo A, Carmona-Garcia MC, Marcos-Gragera R. Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: results from the Girona cancer registry (1994–2013). Cancer Epidemiol. 2017;50(Pt A):1–8.CrossRef
2.
Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, Tourdias T, Kantor G, Maire JP, Vital A, Loiseau H. Gironde TSNC registry group. Descriptive epidemiology of CNS tumors in France: results from the gironde registry for the period 2000–2007. Neuro Oncol. 2011;13(12):1370–8.CrossRef
3.
Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, Pawlish K, Yanik EL, Suneja G, Engels EA. Trends in primary central nervous system lymphoma incidence and survival in the US. Br J Haematol. 2016;174(3):417–24.CrossRef
4.
Enblad G, Martinsson G, Baecklund E, Hesselager G, Sundström C, Amini RM, Hagberg H. Population-based experience on primary central nervous system lymphoma 2000–2012: the incidence in increasing. Acta Oncol. 2017;56(4):599–607.CrossRef
5.
Eloranta S, Brånvall E, Celsing F, Papworth K, Ljungqvist M, Enblad G, Ekström-Smedby K. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000–2013. Eur J Haematol. 2018;100(1):61–8.CrossRef
6.
Krogh-Jensen M, D’Amore F, Jensen MK, Christensen BE, Thorling K, Pedersen M, Johansen P, Boesen AM, Andersen E. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry. Leuk Lymphoma. 1995;19(3–4):223–33.CrossRef
7.
van der Sanden GA, Schouten LJ, van Dijck JA, van Andel JP, van der Maazen RW, Coebergh JW, Working Group of Specialists in Neuro-Oncology in the Southern and Eastern Netherlands. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer. 2002;94(5):1548–56.CrossRef
8.
Lutz JM, Coleman MP. Trends in primary cerebral lymphoma. Br J Cancer. 1994;70:716–8.CrossRef
Metadata
Title
Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994–2013)
Authors
R. Fuentes-Raspall
M. Solans
C. Auñon-Sanz
M. Saez
R. Marcos-Gragera
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1890-8

Other articles of this Issue 12/2018

Clinical and Translational Oncology 12/2018 Go to the issue

Research Article

Radiolabeled F(ab′)2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models

Research Article

Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer

Brief Research Article

Patterns of increased incidence and survival of cutaneous melanoma in Girona (Spain) 1994–2013: a population-based study

Research Article

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

Review Article

New physical approaches to treat cancer stem cells: a review

Research Article

Prospective analysis of psychological differences between adult and elderly cancer patients during postoperative adjuvant chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits